103260-44-2

Basic information

• Product Name: ETHYL TETRAHYDROPYRAN-4-YL-ACETATE
• Synonyms: ETHYL 2-(TETRAHYDRO-2H-PYRAN-4-YL)ACETATE;ETHYL TETRAHYDROPYRAN-4-YL-ACETATE;tetrahydropyran-4-yl-acetate ethyl ester;Ethyl tetrahydropyran-4-acetate;Ethyl tetrahydropyranyl-4...;Ethyl tetrahydropyranyl-4-acetate;Ethyl 2-(4-Tetrahydropyranyl)acetate;(Tetrahydropyran-4-yl)acetic acid ethyl ester
• CAS NO: 103260-44-2
• Molecular Formula: C₉H₁₆O₃
• Molecular Weight: 172.22
• Product Categories: blocks;Carboxes;Heterocycles
• Mol File: 103260-44-2.mol

Chemical Properties

• Boiling Point: 73-75 0,2mm
• Flash Point: 96.7 °C
• Appearance: /
• Density: 1.003 g/cm³
• Vapor Pressure: 0.0739mmHg at 25°C
• Refractive Index: 1.4572 (13.4℃)
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: ETHYL TETRAHYDROPYRAN-4-YL-ACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL TETRAHYDROPYRAN-4-YL-ACETATE(103260-44-2)
• EPA Substance Registry System: ETHYL TETRAHYDROPYRAN-4-YL-ACETATE(103260-44-2)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36-36/37/39-23
• Hazardous Substances Data: 103260-44-2(Hazardous Substances Data)

Usage

Uses

Used in Food and Beverage Industry:
Ethyl tetrahydropyran-4-yl-acetate is used as a flavoring agent for adding a sweet, fruity aroma to various food and beverage products. Its scent profile, which hints at pear and apple, makes it a popular choice for enhancing the taste and aroma of flavored drinks, confectionery, and baked goods.
Used in Fragrance Industry:
In the fragrance industry, ethyl tetrahydropyran-4-yl-acetate serves as a key component in creating perfumes and other scented products. Its distinct and appealing aroma contributes to the development of complex and attractive fragrances that are used in personal care and household products.
Used in Cleaning and Household Products:
Ethyl tetrahydropyran-4-yl-acetate is also utilized in cleaning and household products to provide a pleasant odor. Its inclusion in these products ensures that they not only clean effectively but also leave a fresh and enjoyable scent, enhancing the overall consumer experience.

InChI:InChI=1/C9H16O3/c1-2-12-9(10)7-8-3-5-11-6-4-8/h8H,2-7H2,1H3

Upstream product

• 130312-00-4 ethyl tetrahydro-4H-pyran-4-ylideneacetate 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 

Downstream Products

• 4677-18-3 2-(tetrahydropyran-4-yl)-ethanol 
• 156002-64-1 methyl 2-(tetrahydro-2H-pyran-4-yl)acetate 
• 85064-61-5 2-(tetrahydro-2H-pyran-4-yl)acetic acid 
• 287393-54-8 2-{[4-(2-butynyloxy)phenyl]sulfonyl}(tetrahydro-2H-pyran-4-yl)ethyl acetate 
• 65626-23-5 2-(tetrahydro-2H-pyran-4-yl)acetaldehyde 
• 100-76-5 Quinuclidine 
• 1420039-48-0 benzyl 2-hydroxy-2-(tetrahydro-2H-pyran-4-yl)acetate 
• 1420039-50-4 benzyl 2-oxo-2-(tetrahydro-2H-pyran-4-yl)acetate 
• 1428129-06-9 4-(2-(2-(bromomethyl)-4-chlorophenoxy)ethyl)tetrahydro-2H-pyran 
• 1428129-08-1 (5-chloro-2-(2-(tetrahydro-2H-pyran-4-yl)ethoxy)phenyl)methanol 
• 1428129-07-0 5-chloro-2-(2-(tetrahydro-2H-pyran-4-yl)ethoxy)benzaldehyde 
• 1312016-63-9 5-methoxy-2-[2-(tetrahydro-pyran-4-yl)-1(R)-(4-trifluoromethyl-phenyl)-ethyl]-1H-pyrrolo[2,3-b]pyridine 

Relevant articles and documents

NEW MACROCYCLIC LRRK2 KINASE INHIBITORS

Compounds of formula (I): wherein R, X1, X2, X3, Z1, Z2, Z3, A and Ra are as defined in the description. Medicaments.

Dihydropyrrolopyridine inhibitors of ROR-gamma

Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORγ. Also provided are pharmaceutical compositions co

ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (S-I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.

DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA

Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORy. Also provided are pharmaceutical compositions co

NDM INHIBITOR

An objective of the present invention is to provide a novel NDM (New Delhi metallo-β-lactamase) inhibitor that functions as a drug for restoring the antibacterial activity of β-lactam antibiotics that have been inactivated as a result of decomposition by NDM. According to the present invention, there is provided an NDM inhibitor contains a compound represented by general formula (I):

EP1 RECEPTOR LIGANDS

The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP1 receptor as well as to pharmaceutical compositions comprising them.

AZAINDOLE GLUCOKINASE ACTIVATORS

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

Synthesis of bicyclic tertiary α-amino acids

Novel bicyclic α-amino acids, exo and endo-1-azabicyclo-[2.2.1] heptane-2-carboxylic acid, 1-azabicyclo[2.2.1]heptane-7-carboxylic acid, and 1-azabicyclo[3.2.2]nonane-2-carboxylic acid have been readily synthesized for the generation of neuronal nicotinic receptor ligands. Alkylation of glycine-derived Schiff bases or nitroacetates with cyclic ether electrophiles, followed by acid-induced ring opening and cyclization in NH4OH, allowed for the preparation of substantial quantities of the three tertiary bicyclic α-amino acids.

3-CYCLOALKYLCARBONYL INDOLES AS CANNABINOID RECEPTOR LIGANDS

The present invention provides novel compounds of Formula (I), which are CB2 selective ligands useful for the treatment of pain.

New high affinity H3 receptor agonists without a basic side chain

In this study, we replaced the basic amine function of the known histamine H3 receptor agonists imbutamine or immepip with non-basic alcohol or hydrocarbon moieties. All compounds in this study show a moderate to high affinity for the cloned human H3 receptor and, unexpectedly, almost all of them act as potent agonists. Moreover, in the alcohol series, we consistently observed an increased selectivity for the human H3 receptor over the human H4 receptor, but none of the compounds in this series possess increased affinity and functional activity compared to their alkylamine congeners. In this new series of compounds VUF5657, 5-(1H-imidazol-4-yl)-pentan-1-ol, is the most potent histamine H3 receptor agonist (pKi = 8.0 and pEC50 = 8.1) with a 320-fold selectivity at the human H3 receptor over the human H 4 receptor.